Comparative Pharmacology
Head-to-head clinical analysis: AZASITE versus PROKLAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZASITE versus PROKLAR.
AZASITE vs PROKLAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.
PROKLAR (clarithromycin) is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation.
1 drop of 1% ophthalmic solution to each affected eye twice daily (approximately 12 hours apart) for 2 days, then once daily for 5 days.
500 mg orally every 12 hours for 7-14 days.
None Documented
None Documented
Terminal elimination half-life: 68-72 hours; facilitates once-weekly dosing for trachoma.
Terminal elimination half-life: 2-4 hours (prolonged to 6-8 hours in hepatic impairment); context: requires q8-12h dosing in normal renal function
Primarily hepatic/biliary (fecal) as unchanged drug: ~70% fecal, ~20% renal (mostly unchanged), ~0.5% urinary as metabolites.
Renal: 20-30% unchanged; fecal: 15-30%; biliary: 5-10%; total renal excretion of metabolites: ~70%
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic